Progression‑free survival (PFS) has become a common benchmark in follicular lymphoma trials, yet many patients struggle to understand what the metric means for their daily lives. In a recent interview, Tara Graff, DO, MS described how she translates PFS data into plain‑language conversations that focus on quality of life and practical treatment decisions.
Putting Numbers Into Patient‑Friendly Terms
Graff avoids clinical jargon when discussing trial results. Instead of using technical terms, she frames the statistic as “how long the disease is likely to stay under control.” She lines up treatment options side by side, offering patients a straightforward comparison of expected remission periods.
“I try to give them an estimate of how many months they might expect to feel well without the disease getting worse,” she explained. This approach helps patients weigh the benefits of a new therapy against the potential side effects and the disruption to their routine.
She also highlights the importance of “time to next therapy” (TTNT) as a complementary metric. In follicular lymphoma, which often runs a slow course, patients can notice early signs of progression while still feeling fine. The interval between the first hint of growth and the point when another treatment is needed can represent a valuable stretch of disease‑free living.
Related: User Blocked from Social Media Platform
Why Time to Next Therapy Matters
According to Graff, TTNT can be especially relevant when the disease is indolent. “Patients may be living well for months after the first sign of progression,” she noted, “so that gap should be part of the conversation.” By emphasizing both PFS and TTNT, clinicians can provide a fuller picture of what patients might expect after starting a new regimen.
She adds that for a chronic, relapsing condition like follicular lymphoma, these two metrics serve as “important anchors” in shared decision‑making. The goal, she says, is to align treatment choices with the patient’s personal priorities, whether that means extending the time without symptoms or minimizing the number of therapy cycles.
In practice, the emphasis on TTNT may shift how providers counsel patients about newer, chemo‑free options that promise longer remission periods without the traditional toxicity profile. This reflects a broader trend toward patient‑centered metrics that go beyond simple survival curves.
One awkward phrase that slipped in was “the interval between first signs of progression and the actual need for the next treatment can itself represent a meaningful period of disease‑free living that deserves to be part of the patient conversation.” The sentence feels a bit tangled, but it captures the nuance Graff is trying to convey.
Related: User access denied after system block
When comparing this approach to past practices, it resembles earlier moves in oncology to replace “overall survival” with more patient‑relevant endpoints, such as symptom‑free intervals. While the field has not fully standardized TTNT as a primary endpoint, the growing attention mirrors how clinicians have gradually incorporated quality‑of‑life measures into trial designs.
Future Directions in Community Practice
Graff’s discussion sets the stage for the next episode in the series, which will focus on lenalidomide plus rituximab (R²) as a second‑line option. She plans to explore which patients are best suited for this chemo‑free regimen and how community oncologists can integrate it into their practice.
By keeping the conversation grounded in patient‑centered outcomes, the series aims to help clinicians manage the complex decisions that arise when treating relapsed follicular lymphoma. Clear communication and realistic expectations may ultimately improve adherence and satisfaction among patients facing chronic disease management.
